{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:59:19Z","timestamp":1792508359827,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.bbmt.2020.07.028","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T14:18:18Z","timestamp":1595945898000},"page":"2068-2074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Vasant","family":"Chinnabhandar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Mechinaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Tapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lochie","family":"Teague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey A.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2020.07.028_bib0001","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0003","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0004","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2013-10-532598","article-title":"Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study","volume":"123","author":"Conter","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1703601","article-title":"Allogeneic bone marrow transplantation for childhood relapsed acute lymphoblastic leukemia: comparison of outcome in patients with and without a matched family donor","volume":"30","author":"Bleakley","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0006","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.bbmt.2009.05.005","article-title":"Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors","volume":"15","author":"Smith","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0007","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors\u2014the ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.bbmt.2017.04.015","article-title":"Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission","volume":"23","author":"Page","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0009","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bjh.12639","article-title":"Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?","volume":"164","author":"Balduzzi","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0010","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2012.48.5680","article-title":"Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group","volume":"31","author":"Eckert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0011","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","article-title":"Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial","volume":"33","author":"Bader","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0012","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/bjh.12749","article-title":"Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol","volume":"165","author":"Gandemer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.13142","article-title":"Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia","volume":"168","author":"Sutton","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0014","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2000.18.2.340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.bmt.1705515","article-title":"Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens","volume":"38","author":"Gassas","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0016","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0017","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbmt.2012.09.019","article-title":"Transplantation conditioning regimens and outcomes after allogeneic hematopoietic cell transplantation in children and adolescents with acute lymphoblastic leukemia","volume":"19","author":"Tracey","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0018","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/pbc.25602","article-title":"Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: a study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation","volume":"62","author":"Kato","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0019","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1704605","article-title":"Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia","volume":"34","author":"Dai","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0020","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbmt.2017.11.025","article-title":"Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia","volume":"24","author":"Kebriaei","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0021","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","article-title":"Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: a comparative study","volume":"97","author":"Sakellari","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/ctrv.2000.0170","article-title":"Chemistry, pharmacology and pharmacokinetics of N,N',N\" -triethylenethiophosphoramide (ThioTEPA)","volume":"26","author":"Maanen","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0023","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/bmt.2015.264","article-title":"Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients","volume":"51","author":"Pasqualini","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0024","first-page":"31","article-title":"Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I\/II study","volume":"53","author":"Cohen","year":"2015","journal-title":"A report from the Children's Oncology Group. Pediatr Neurol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bmt.1705211","article-title":"Unrelated donor or partially matched related donor peripheral stem cell transplant with CD34+ selection and CD3+ addback for pediatric patients with leukemias","volume":"37","author":"Bunin","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0026","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/10428194.2011.631159","article-title":"Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant","volume":"53","author":"Ciurea","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0027","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.3109\/10428194.2014.889825","article-title":"Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma","volume":"55","author":"Kokolo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0028","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.12553","volume":"96","author":"Eder","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0029","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.1999.17.6.1838","article-title":"Total body irradiation, thiotepa, and cyclophosphamide as a conditioning regimen for children with acute lymphoblastic leukemia in first or second remission undergoing bone marrow transplantation with HLA-identical siblings","volume":"17","author":"Zecca","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0030","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0031","first-page":"247","article-title":"Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease","volume":"4","author":"Atkinson","year":"1989","journal-title":"Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0032","unstructured":"A language and environment for statistical computing. The R Foundation Oct 27th 2019. Available at: https:\/\/www.R-project.org\/."},{"key":"10.1016\/j.bbmt.2020.07.028_bib0033","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2020.07.028_bib0034","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","article-title":"More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling","volume":"3","author":"Bader","year":"2019","journal-title":"Blood Adv"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879120304614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:54Z","timestamp":1761059634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879120304614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1083879120304614"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of Thiotepa to Total Body Irradiation and Cyclophosphamide Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}